In the PAPILLON Study, First-Line Amivantamab-Chemotherapy Demonstrates the Longest Overall Survival Reported for EGFR Exon 20 Insertion-Positive Advanced NSCLC
September 13, 2026
September 13, 2026
AURORA, Colorado, Sept. 13 [Category: Medical] -- The International Association for the Study of Lung Cancer posted the following news release:
* * *
In the PAPILLON Study, First-Line Amivantamab-Chemotherapy Demonstrates the Longest Overall Survival Reported for EGFR Exon 20 Insertion-Positive Advanced NSCLC
*
(SEOUL, Republic of Korea -September 14th at 10:45 a.m. Korea Standard Time) -Results from the Phase III PAPILLON study show that first . . .
* * *
In the PAPILLON Study, First-Line Amivantamab-Chemotherapy Demonstrates the Longest Overall Survival Reported for EGFR Exon 20 Insertion-Positive Advanced NSCLC
*
(SEOUL, Republic of Korea -September 14th at 10:45 a.m. Korea Standard Time) -Results from the Phase III PAPILLON study show that first . . .